



October 1, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2017-002925-39 / Novartis Protocol ID CMAA868A2201

A multicenter, randomized, open-label, blinded endpoint evaluation, active-controlled Phase 2 study to compare the efficacy and safety of s.c. MAA868 versus s.c. enoxaparin in adult patients undergoing unilateral total knee arthroplasty

Trial CMAA868A2201 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.

